Expense

Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Friday, May 12, 2023
Insurance, Human resources, DevOps, Cash, Senior, B cell, Research, MDS, Public expenditure, AML, Expense, Patient, Administration, Transplant, Conditional sentence, Research and development, R, CD117, Therapy, Pharmaceutical industry, Management, Cryptocurrency, Jasper

“We also secured substantial additional capital to support our development plans across the briquilimab franchise.

Key Points: 
  • “We also secured substantial additional capital to support our development plans across the briquilimab franchise.
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended March 31, 2023 were $9.8 million compared to $8.2 million for the quarter ended March 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the quarter ended March 31, 2023 were $4.1 million compared to $4.6 million for the quarter ended March 31, 2022.
  • Net Loss: For the quarter ended March 31, 2023, net loss was $14.3 million compared to net loss of $2.2 million for the quarter ended March 31, 2022.

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, May 12, 2023
SAB, Insurance, Orchestra, Medical Affairs Bureau, Partnership, Investment, Health, Virtue, ISR, Beat (music), Research, Development, Expense, Acquisition, Patient, Physician, Administration, RTW, CNT, R, SVP, Pharmaceutical Development and Technology, Management, Cryptocurrency, Pharmaceutical industry, Video game, HOPE, Innovation, Quality, Medtronic

NEW HOPE, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial results and provided a business update.

Key Points: 
  • NEW HOPE, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial results and provided a business update.
  • “The first quarter of 2023 was a transformational period for Orchestra BioMed marked by our successful entrance into the public markets.
  • Revenue: Orchestra BioMed recognized $1.2 million of revenue for the first quarter of 2023 compared to $0.9 million for the first quarter of 2022.
  • Other Income (Expense): Other income was $0.6 million for the first quarter of 2023, compared to other expense of $0.6 million for the first quarter of 2022.

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Insulin, Research and development, VTV, G&A, Expense, Patient, Administration, R, FDA, General Administration of Sport of China, Therapy, G42, Pharmaceutical industry, T1D

HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.
  • As of March 31, 2023, the Company’s cash and cash equivalents totaled approximately $18.8 million.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended March 31, 2023, was $4.5 million or $0.06 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $7.0 million or $0.10 per basic share.

Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Health, Clinical Trials, Other Health, Patent, Partnership, University, IPSC, Lineage, Lab, AMD, Expense, Roche, California Institute for Regenerative Medicine, Beta-2 microglobulin, Geographic atrophy, G&A, Research, GA, Genentech, Accounting, Interest, Regenerative medicine, MRI, Ophthalmology, Magnetic resonance imaging, Patient, Investment, Manuscript, TASE, CIRM, NYSE American, Webcast, Lineage Cell Therapeutics, SCI, United States Patent and Trademark Office, FDA, Therapy, IND, Asterias, D, Pharmaceutical industry, Fine chemical, Medical imaging, Medical device, Cryptocurrency, Otorhinolaryngology

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter ended March 31, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter ended March 31, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.
  • “During the first quarter of this year, the Lineage team executed on multiple fronts, advancing our clinical and preclinical cell transplant programs while continuing support of our existing alliances and establishing new ones,” stated Brian M. Culley, Lineage CEO.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

LiqTech International Announces First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
EURO, USD, Expense, Traction, Water, ESG, Hand, Video game, Film industry, Pharmaceutical industry, Cryptocurrency

BALLERUP, Denmark, May 11, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the first quarter of 2023 for the period ended March 31, 2023.

Key Points: 
  • BALLERUP, Denmark, May 11, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the first quarter of 2023 for the period ended March 31, 2023.
  • Fei Chen, CEO of LiqTech, stated, "The commercial strategy we put into place is beginning to deliver the intended results.
  • The Company expects Q2 2023 revenue of approximately $5.0 million, compared to $4.0 million for Q1 2023.
  • Replay: A teleconference replay of the call will be available until May 18, 2023, at (877) 344-7529 or (412) 317-0088, confirmation # 3502560.

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Retrieved on: 
Wednesday, May 10, 2023
Workforce, Therapy, Development, Regeneration, Expense, Administration, SAN, Chronic liver disease, Research, Safety, Pharmaceutical industry, Cryptocurrency, WNT

SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2023 financial results and corporate and pipeline updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2023 financial results and corporate and pipeline updates.
  • Financial Results for the First Quarter Ended March 31, 2023
    Cash Position: Cash, cash equivalents and marketable securities for the first quarter ended March 31, 2023 were $61.7 million, compared to $75.8 million as of December 31, 2022.
  • Restructuring: Restructuring charges for the first quarter ended March 31, 2023 were $1.2 million, as compared to zero for the same period in 2022.
  • Net Loss: Net loss for the first quarter ended March 31, 2023 was $14.3 million, as compared to $7.9 million for the same period in 2022.

eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Abstract, PRS, Metastatic breast cancer, American Society of Clinical Oncology, Cancer, Fulvestrant, STRI Group, G&A, Net operating loss, MNK, NSCLC, Effector, Lung cancer, Messenger, Cell, Assistant, Science, ASCO, QW, Expense, Patient, Investment, Administration, KICKSTART, Stanford University School of Medicine, Artificial intelligence, Research and development, R, Research, Pembrolizumab, Therapy, Safety, PD-L1, Society, ER, Breast cancer, Pharmaceutical industry, Vaccine, Cryptocurrency, Medicine, Genetics

SOLANA BEACH and REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Clinical data for zotatifin-based combination regimens in ER+ breast cancer have been selected for presentation at ASCO Annual Meeting 2023.
  • Management also intends to host a conference call to discuss results and further development of zotatifin during ASCO 2023.
  • Research and Development (R&D) Expenses: R&D expenses were $6.6 million for the quarter ended March 31, 2023, compared to $3.1 million for the same quarter of 2022.
  • Other expense in the quarter ended March 31, 2023 consisted primarily of interest expense associated with the company’s term loans.

MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Histology, CPI, Hepatocellular carcinoma, Survival, Cancer, G&A, Research, NSCLC, Liver cancer, Administration, Science, Expense, Patient, Liver, Research and development, R, IND, NYSE, HCC, Safety, Pharmaceutical industry, Cryptocurrency, Part

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
  • Research and Development (R&D) Expenses: R&D expenses were approximately $2.2 million for the quarter ended March 31, 2023, compared to approximately $2.1 million for quarter ended March 31, 2022.
  • Other Income (Expense): Other income was approximately $0.07 million for the quarter ended March 31, 2023, and other expense for the quarter ended March 31, 2022 was approximately $0.03 million.
  • Net Income (Loss): Net loss was approximately $4.1 million for the quarter ended March 31, 2023, as compared to net loss of approximately $3.9 million for the quarter ended March 31, 2022.

CNH Industrial Reports Record First Quarter 2023 Results

Retrieved on: 
Friday, May 5, 2023
Net, Uncertainty, European Free Trade Association, EU, Table, Financial services, CNH Industrial, GAAP, EBIT, Continental, CNH, Expense, Investment, Nature, Collection, FX, European, United Kingdom, EPS, Adjustment, Industrial, Real estate, Cryptocurrency, Bank, Risk management, Renting

The Company is therefore updating the 2023 outlook for its Industrial Activities:

Key Points: 
  • The Company is therefore updating the 2023 outlook for its Industrial Activities:
    CNH Industrial reports quarterly and annual consolidated financial results under U.S. GAAP and EU-IFRS.
  • CNH Industrial’s management believes that these non-GAAP financial measures provide useful and relevant information regarding its operating results and enhance the readers’ ability to assess CNH Industrial’s financial performance and financial position.
  • Adjusted EBIT Margin of Industrial Activities: is computed by dividing Adjusted EBIT of Industrial Activities by Net Sales of Industrial Activities.
  • CNH Industrial provides the reconciliation of Net Cash (Debt) to Total (Debt), which is the most directly comparable measure included in the consolidated balance sheets.

Kontoor Brands Reports 2023 First Quarter Results; Reaffirms 2023 Outlook

Retrieved on: 
Thursday, May 4, 2023
Men, Family, Discount, Variety, Department Stores, Consumer, Fashion, Teens, Textiles, Retail, Children, Women, Manufacturing, Lee, DTC, Pressure, Kontoor Brands, Interest, SG, Line of credit, Brand, Capital expenditure, GAAP, Ratio, COVID, KTB, Internet, Expense, EBITDA, Investment, Depreciation, Administration, Wrangler, Growth, EPS, General Administration of Press and Publication, NYSE, Clothing, Marketing, Bank, Pharmaceutical industry, Video game, Security (finance), Renewable energy, International

“We delivered first quarter results consistent with our expectations and commentary provided on the fourth quarter earnings call.

Key Points: 
  • “We delivered first quarter results consistent with our expectations and commentary provided on the fourth quarter earnings call.
  • As anticipated, our brands continued to gain share in the U.S. where POS outpaced shipments in the quarter.
  • The Company is reaffirming its prior outlook for FY’23 provided on February 28, 2023, with select updates to quarterly cadence.
  • Kontoor Brands will host its first quarter conference call beginning at 8:30 a.m. Eastern Time today, May 4, 2023.